KaydedilenlerDerginizi ekleyin

Dergiler / Fabad Eczacılık Bilimler Dergisi / 2023 / Cilt: 48 Sayı: 2

Interaction of Statins with Grapefruit Juice

Müge ATEŞ
Selma ŞAHİN
Sayfa
337–358
Yayın Tarihi
2023-08-01
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Therefore, patients using statins are generally advised to avoid grapefruit juice consumption.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Grapefruit juice, which discovered to interact with felodipine for the first time, is now known to interact with more that 80 drugs.
📊
Temel Bulgular & Veri:Grapefruit juice-statin interactions were first investigated in 1998 in human pharmacokinetic studies with lovastatin and simvastatin.
💡
Sonuç & Katkı:Therefore, patients using statins are generally advised to avoid grapefruit juice consumption.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Grapefruit juice · drug interaction · statins

Abstract

Grapefruit juice, which discovered to interact with felodipine for the first time, is now known to interact with more that 80 drugs. Statins are among the drugs that interact with grapefruit juice. Grapefruit juice-statin interactions were first investigated in 1998 in human pharmacokinetic studies with lovastatin and simvastatin. The pharmacokinetic and pharmacodynamic basis of the interaction has been extensively investigated in studies. Flavonoids and furanocoumarins, the main components of grapefruit juice, have been reported to cause drug interactions. Furthermore, statin-grapefruit juice interactions occur mostly through inhibition of cytochrome-3A4 (CYP3A4), to a lesser extent through inhibition of P-glycoprotein (P-gp) and organic anion transporting polypeptides (OATPs). Changes in plasma drug levels as a result of interaction may increase the side-effect of statins or reduce their therapeutic efficacy. Therefore, patients using statins are generally advised to avoid grapefruit juice consumption.

🔖

Bu Makaleye Atıf Yap

ATEŞ, M., ŞAHİN, S. (2023). Interaction of Statins with Grapefruit Juice. Fabad Eczacılık Bilimler Dergisi, Cilt: 48 Sayı: 2, 337–358. https://ajindex.com/articles/958206

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. Amly, W., Karaman, R. (2015). Commonly used drugs uses, side effects, bioavailability and approaches to improve it. 1th ed. Nova Science Publishers, USA, 131-172.
  2. Ando, H., Tsuruoka, S., Yanagihara, H., Sugimoto, K.I., Miyata, M., Yamazoe, Y., Takamura, T., Kaneko, S., Fujimura, A. (2005). Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. British Journal of Clinical Pharmacology, 60(5), 494-497. doi: 10.1111/j.1365-2125.2005.02462.x. Bailey, D.G., Spence, J.D., Edgar, B., Bayliff, C.D., Arnold, J.M. (1989). Ethanol enhances the hemodynamic effects of felodipine. Clinical and Investigative Medicine, 12(6), 357-362.
  3. Bailey, D.G., Kreeft, J.H., Munoz, C., Freeman, D.J., Bend, J.R. (1998). Grapefruit juice-felodipine interaction: Effect of naringin and 6’,7’-dihydroxybergamottin in humans. Clinical Pharmacology & Therapeutics, 64(3), 248-256. doi: https://doi.org/10.1016/S0009-9236(98)90173-4.
  4. Bailey, D.G., Dresser, G.K. (2004). Interactions between grapefruit juice and cardiovascular drugs. American Journal of Cardiovascular Drugs, 4(5), 281-297. doi: https://doi.org/10.2165/00129784-200404050-00002.
  5. Bailey, D.G. (2010). Fruit juice inhibition of uptake transport: a new type of food–drug interaction. British Journal of Clinical Pharmacology, 70(5), 645-655. doi: 10.1111/j.1365-2125.2010.03722.x Bailey, D.G., Dresser, G., Arnold, M.O. (2013). Grapefruit–medication interactions: Forbidden fruit or avoidable consequences? Canadian Medical Association Journal, 185(4), 309-316. doi: https://doi.org/10.1503/cmaj.120951.
  6. Bang, L.M., Goa, K.L. (2003). Pravastatin a review of its use in elderly patients. Drugs Aging, 20(14), 1061-1082. doi: https://doi.org/10.2165/00002512-200320140-00005.
  7. Bellosta, S., Paoletti, R., Corsini, A. (2004). Safety of statins focus on clinical pharmacokinetics and drug Interactions. Circulation, 109(23), 50-57. doi: 10.1161/01.CIR.0000131519.15067.1f. Bonsu, K.O., Kadirvelu, A., Reidpath, D.D. (2013). Lipophilic versus hydrophilic statin therapy for heart failure: a protocol for an adjusted indirect comparison meta-analysis. Systematic Reviews, 2(22), 1-7. doi: 10.1186/2046-4053-2-22.
  8. Carella, A.M., Marinelli, T., Melfitano, A., Di Pumpo, M., Conte, M., Modola, G., Puntonio, M.C., Benvenuto, A. (2016). Focus on pitavastatin. International Journal of Cardiology and Lipidology Research, 3, 11-19. doi: http://dx.doi.org/10.15379/2410-2822.2016.03.01.03
  9. Carswell, C.I., Plosker, G.L., Jarvis, B. (2002). Rosuv